Last reviewed · How we verify

South China Children's Leukemia Group — Portfolio Competitive Intelligence Brief

South China Children's Leukemia Group pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
MTX MTX marketed Antimetabolite; folate antagonist Dihydrofolate reductase (DHFR) Oncology
RIF RIF marketed Rifamycin antibiotic Bacterial RNA polymerase Oncology (supportive care) / Infectious Disease
ATO ATO marketed Arsenic compound; differentiation agent PML-RARA fusion protein; mitochondrial apoptotic pathways Oncology
ATRA ATRA marketed Retinoid; differentiation agent Retinoic acid receptor (RAR), particularly RAR-alpha Oncology
6MP 6MP marketed Purine analog antimetabolite Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University of California, San Francisco · 2 shared drug classes
  2. Bausch Health Americas, Inc. · 1 shared drug class
  3. French Innovative Leukemia Organisation · 1 shared drug class
  4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  5. Chinese PLA General Hospital · 1 shared drug class
  6. Chonnam National University Hospital · 1 shared drug class
  7. Case Comprehensive Cancer Center · 1 shared drug class
  8. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for South China Children's Leukemia Group:

Cite this brief

Drug Landscape (2026). South China Children's Leukemia Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/south-china-children-s-leukemia-group. Accessed 2026-05-16.

Related